Dyadic partners with Scripps Research on hantavirus antibody and vaccine development

Dyadic International announced a collaboration with Scripps Research to develop monoclonal antibody and vaccine candidates targeting hantaviruses using its C1 microbial platform. The partnership leverages prior infectious disease research and aims to accelerate biologic production for pandemic preparedness applications.